December 2007, Vol 99 (supplement 2)
Misoprostol dosage recommendations from an expert committee who met in Bellagio, Italy in Feb 2007.
Forward – Misoprostol for reproductive health – D. Shaw, President FIGO
Introduction – Misoprostol in obstetrics and gynecology –
Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects.
O.S. Tang, K. Gemzell-Danielsson and P.C. Ho
Cervical priming with misoprostol prior to transcervical procedures.
C. Fiala, K. Gemzell-Danielsson, O.S. Tang and H. von Hertzen
Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy.
A. Faúndes, C. Fiala, O.S. Tang and A. Velasco
Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks.
P.C. Ho, P.D. Blumenthal, K. Gemzell-Danielsson, R. Gómez Ponce de Leon, S. Mittal and O.S. Tang
Misoprostol to treat missed abortion in the first trimester.
K. Gemzell-Danielsson, P.C. Ho, R. Gómez Ponce de León, A. Weeks and B. Winikoff<
Treatment of incomplete abortion and miscarriage with misoprostol.
J. Blum, B. Winikoff, K. Gemzell-Danielsson, P.C. Ho, R. Schiavon and A. Weeks
Misoprostol for intrauterine fetal death.
R. Gómez Ponce de León, D. Wing and C. Fiala
Misoprostol for induction of labor with a live fetus
A. Weeks, Z. Alfirevic, A. Faúndes, G.J. Hofmeyr, P. Safar and D. Wing
Prevention of postpartum hemorrhage with misoprostol.
Z. Alfirevic, J. Blum, G. Walraven, A. Weeks and B. Winikoff
Treatment of postpartum hemorrhage with misoprostol.
J. Blum, Z. Alfirevic, G. Walraven, A. Weeks and B. Winikoff